ACP
Altitude Crest Partners Portfolio holdings
AUM
$234M
This Quarter Return
+28.31%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$234M
AUM Growth
+$234M
(+56%)
Cap. Flow
+$90.1M
Cap. Flow
% of AUM
38.56%
Top 10 Holdings %
Top 10 Hldgs %
69.27%
Holding
34
New
22
Increased
2
Reduced
4
Closed
4
Top Buys
| 1 |
Stevanato
STVN
|
$17.7M |
| 2 |
Thermo Fisher Scientific
TMO
|
$10.7M |
| 3 |
ArriVent BioPharma
AVBP
|
$9.92M |
| 4 |
Structure Therapeutics
GPCR
|
$8.79M |
| 5 |
Apellis Pharmaceuticals
APLS
|
$7.94M |
Top Sells
| 1 |
argenx
ARGX
|
$11.2M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$11M |
| 3 |
Exact Sciences
EXAS
|
$7.33M |
| 4 |
BridgeBio Pharma
BBIO
|
$4.41M |
| 5 |
Roivant Sciences
ROIV
|
$3.72M |
Sector Composition
| 1 | Healthcare | 99.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Legend Biotech
LEGN
$6.41B
| $36.6M | 15.67% | 652,732 +110,916 | +20% | +$6.22M |
|
2
Danaher
DHR
$147B
| $27.1M | 11.62% | 108,700 -12,900 | -11% | -$3.22M |
|
|
3
BridgeBio Pharma
BBIO
$9.89B
| $18.9M | 8.1% | 612,060 -142,500 | -19% | -$4.41M |
|
|
4
Stevanato
STVN
$6.28B
| $17.7M | 7.56% | +550,000 | New | +$17.7M |
|
|
5
Apellis Pharmaceuticals
APLS
$3.48B
| $16.9M | 7.23% | 287,277 +135,077 | +89% | +$7.94M |
|
|
6
Thermo Fisher Scientific
TMO
$186B
| $10.7M | 4.58% | +18,400 | New | +$10.7M |
|
|
7
ArriVent BioPharma
AVBP
$776M
| $9.92M | 4.25% | +555,555 | New | +$9.92M |
|
|
8
Structure Therapeutics
GPCR
$1.11B
| $8.79M | 3.76% | +205,166 | New | +$8.79M |
|
9
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $7.9M | 3.38% | 400,441 -55,600 | -12% | -$1.1M |
|
10
Janux Therapeutics
JANX
$1.37B
| $7.28M | 3.12% | +193,300 | New | +$7.28M |
|
11
Eli Lilly
LLY
$657B
| $7.16M | 3.06% | +9,200 | New | +$7.16M |
|
12
Biohaven
BHVN
$1.63B
| $6.47M | 2.77% | +118,380 | New | +$6.47M |
|
13
Immunome
IMNM
$828M
| $6.47M | 2.77% | +262,284 | New | +$6.47M |
|
|
SWTX
14
DELISTED
SpringWorks Therapeutics
SWTX
| $6.34M | 2.71% | +128,842 | New | +$6.34M |
|
15
Geron
GERN
$893M
| $5.05M | 2.16% | +1,531,400 | New | +$5.05M |
|
16
Icon
ICLR
$13.8B
| $4.97M | 2.13% | +14,800 | New | +$4.97M |
|
17
Merus
MRUS
$4.98B
| $4.95M | 2.12% | +109,837 | New | +$4.95M |
|
|
18
Roivant Sciences
ROIV
$8.15B
| $4.79M | 2.05% | 454,766 -353,295 | -44% | -$3.72M |
|
19
Denali Therapeutics
DNLI
$2.23B
| $4.3M | 1.84% | +209,613 | New | +$4.3M |
|
20
Corbus Pharmaceuticals
CRBP
$115M
| $4.07M | 1.74% | +103,703 | New | +$4.07M |
|
21
Agios Pharmaceuticals
AGIO
$2.19B
| $3.31M | 1.42% | +113,100 | New | +$3.31M |
|
22
Day One Biopharmaceuticals
DAWN
$769M
| $3.23M | 1.38% | +195,497 | New | +$3.23M |
|
23
Aligos Therapeutics
ALGS
$73.3M
| $2.79M | 1.19% | 2,844,681 | – | – |
|
24
enGene Holdings
ENGN
$236M
| $2.04M | 0.87% | +120,289 | New | +$2.04M |
|
25
Applied Therapeutics
APLT
$71M
| $1.77M | 0.76% | +259,700 | New | +$1.77M |
|